Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
High-impact AFib feasibility data and FDA IDE for NANOPULSE-AF, plus an upcoming Q4 call, have driven a ~66% 21-day surge and clear breakout; with minimal revenue and cash-burn risk this is a speculative but genuinely news-driven short-term hot momentum name.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Cash Position ⢠Persistent Cash Burn ⢠Significant Dilution PLSE has strong liquidity and low leverage, but persistent losses, cash burn, dilution, negligible revenue, and an extreme valuation make it a high-risk, financing-dependent investment.
Price Behavior
Key Price Behavior Insights: ⢠Persistent Uptrend ⢠Sharp Pullback ⢠Breakout Watch Support Level: $48.80â$49.00 Resistance Level: $54.70â$55.00 PLSE remains bullish over the last month but volatile, with a breakout above $54.70â$55.00 strengthening momentum while a break below $48.80â$49.00 would weaken the setup.
Sentiment & News
Key News Insights: ⢠Institutional accumulation ⢠Platform momentum ⢠Bullish coverage Pulse Biosciences is gaining momentum from institutional buying, hiring, and bullish analyst coverage around its nanosecond ablation platform.
AI Summary
PLSE is a high-duration bet on NANOPULSE-AF clinical validation and eventual AF ablation adoptionânot its negligible current revenueâso investors should watch for differentiated safety/efficacy data and regulatory progress while recognizing that continued cash burn and likely dilution could drive a sharp rerating if milestones slip.
Description
Pulse Biosciences, Inc. is a bioelectric medicine company that develops the CellFX System, a console-based platform that delivers nanosecond electrical pulses (Nano-Pulse Stimulation) to non-thermally remove targeted cells while sparing surrounding non-cellular tissue. The company was incorporated in 2014, changed its name from Electroblate, Inc. to Pulse Biosciences in December 2015, and is headquartered in Hayward, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Feb 18 | Feb 25 | PLSE | Pulse Biosciences, Inc. | High-impact AFib feasibility data and FDA IDE for NANOPULSE-AF, plus an upcoming Q4 call, have driven a ~66% 21-day surge and clear breakout; with minimal revenue and cash-burn risk this is a speculative but genuinely news-driven short-term hot momentum name. | Closed | -24.6% |
| Feb 11 | Feb 18 | PLSE | Pulse Biosciences, Inc. | FDA IDEs for NANOPULSEâAF and nPulse 360 EP plus strong firstâinâhuman ablation data (150 patients, presented 2026â02â05) triggered a ~75% threeâday jump and price ~55% above its 21âday SMA, making PLSE a highâvolatility clinicalâcatalyst momentum trade into the 2026â02â19 earnings update. | Closed | +0.8% |